Lymphocyte regulation of neuropeptide gene expression after neuronal injury.
The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating peptide (PACAP) are induced strongly in neurons after several types of injury, and exhibit neuroprotective actions in vitro and in vivo. It is thought that changes in expression of neuropeptides and other molecules in injured neurons are mediated by new factors produced in Schwann and immune cells at the injury site, a loss of target-derived factors, or a combination of mediators. To begin to determine the role of the inflammatory mediators, we investigated axotomy-induced changes in VIP and PACAP gene expression in the facial motor nucleus in severe combined immunodeficient (SCID) mice, and in mice with targeted mutations in specific cytokine genes. In normal mice, VIP and PACAP mRNA was induced strongly in facial motor neurons 4 days after axotomy. The increase in PACAP mRNA was blocked selectively in SCID mice, indicating that mechanisms responsible for VIP and PACAP gene induction are not identical. The loss of PACAP gene expression in SCID mice after axotomy was fully reversed by an infusion of normal splenocytes, suggesting that PACAP mRNA induction requires inflammatory mediators. PACAP and VIP mRNA inductions, however, were maintained in mice lacking leukemia inhibitory factor (LIF) and interleukin-6 (IL-6), and in mice lacking both receptors for tumor necrosis factor alpha (TNFalpha). The data suggest that an inflammatory response, most likely involving T lymphocytes, is necessary for the axotomy-induced increase in PACAP but not in VIP. LIF, IL-6, and TNFalpha, however, are not required for this response to injury.
D000818:Animals; D019771:Axotomy; D016207:Cytokines / Q000172:deficiency / Q000235:genetics; D005154:Facial Nerve / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D020220:Facial Nerve Injuries / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D005786:Gene Expression Regulation / Q000276:immunology*; D007249:Inflammation / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D016513:Mice, SCID; D009046:Motor Neurons / Q000378:metabolism* / Q000473:pathology; D009154:Mutation / Q000235:genetics; D009479:Neuropeptides / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012183:Retrograde Degeneration / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D013601:T-Lymphocytes / Q000276:immunology*; D015533:Transcriptional Activation; D015854:Up-Regulation / Q000235:genetics; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism
C495402:Adcyap1 protein, mouse; C495403:Adcyap1 protein, rat; D016207:Cytokines; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012333:RNA, Messenger; D014660:Vasoactive Intestinal Peptide